GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes Filing of GranuFlo Class Action in California State Court
The Firm is investigating GranuFlo lawsuits on behalf of dialysis patients who allegedly suffered catastrophic heart side effects, including heart attacks, strokes, and sudden cardiac death, related to the GranuFlo recall for GranuFlo and NaturaLyte dialysis concentrates.
New York, NY (PRWEB) September 03, 2013
GranuFlo lawsuits (http://www.granuflodialysislawsuits.com/) filed in the wake of the March 2012 recall for GranuFlo and NaturaLyte dialysis concentrates continue to mount in courts throughout the country, Bernstein Liebhard LLP reports. According to court documents, a group of plaintiffs recently filed a GranuFlo class action in California Superior Court. The complaint, which was filed on August 23rd, accuses Fresenius Medical Care of concealing the serious health risks associated with GranuFlo, including its alleged association with heart attack and stroke. (Rodriguez et al. v. Fresenius USA Inc. et al., Case No. BC519374)
“We have heard from numerous patients who suffered serious heart problems, including heart attacks and strokes, following a dialysis treatment with GranuFlo or NaturaLyte. Their experiences echo many of the allegations put forth in the GranuFlo class action lawsuit,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free GranuFlo lawsuit evaluations to dialysis patients who may have been harmed by either of these products.
Court documents indicate that more than 300 GranuFlo lawsuits have been filed in courts around the country on behalf of patients who are alleged to have suffered sudden and life-threatening heart problems following a dialysis treatment with GranuFlo or NaturaLyte. Most of those claims are pending in a multidistrict litigation underway in U.S. District Court, District of Massachusetts. Like the GranuFlo class action, plaintiffs in these individual lawsuits claim that Fresenius Medical Care failed to provide adequate warnings regarding the use of the two drugs, and assert that the company continued to aggressively market the products even after it became aware of their dangers. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
Last year, the U.S. Food & Drug Administration (FDA) announced a Class I GranuFlo recall, after Fresenius issued an “Urgent Product Notification” to its customer clinics warning of possible heart risks associated with the products. According to the FDA, GranuFlo and NaturaLyte have been associated with high levels of bicarbonate in the blood, which can lead to metabolic alkalosis. Metabolic alkalosis is a significant risk factor for serious cardiovascular problems, including low blood pressure and cardiac arrhythmia, which if not treated promptly can lead to cardiopulmonary arrest and sudden cardiac death.
In November 2011, the company issued an internal memo to its own dialysis clinics warning of severe health risks associated with GranuFlo and NaturaLyte. However, according to plaintiffs in GranuFlo lawsuits, that memo was not shared with thousands of other dialysis clinics that purchased GranuFlo and NaturaLyte from Fresenius, or with federal regulators. According to a New York Times report published last summer, the FDA has launched an investigation into Fresenius Medical Care’s timing of the GranuFlo recall.*
Patients and surviving family members of patients who suffered catastrophic heart side effects, including heart attacks, strokes, or sudden cardiac death, within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for their injuries. Read More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, contact a lawyer at Bernstein Liebhard LLP today by calling 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11085470.htm